Abstract 18250: Favorable Modifiable Cardiovascular Risk Profile is Associated With Lower Healthcare Costs Among Cancer Patients: The 2013 Medical Expenditure Survey
Background: Atherosclerotic cardiovascular disease (ASCVD) and cancer are among the leading causes of economic burden, morbidity and mortality in the US. We aimed to quantify the overall impact of CV modifiable risk factor (CRF) profile on health care expenditures among those with and without ASCVD and/or cancer.
Methods: The 2013 Medical Expenditure Panel Survey (MEPS), a nationally representative adult sample (≥ 40), was utilized for the study. Direct costs were calculated for all-cause health care resource utilization. Variables included ASCVD, CRF (HTN, diabetes, hypercholesterolemia, smoking, physical activity and/or obesity), and cancer (all), obtained by ICD-9-CM codes, Clinical Classification System, and self-reported data. Two-part econometric models analyzed cost data; a generalized linear model with gamma distribution and link log assessed expenditures, given the survey’s complex design.
Results: 13,058 MEPS participants (59 ± 9 years, 52% female) were studied and 18% had cancer, translating to 26 million US adults over 40 years of age. A higher prevalence of ASCVD was noted in those with vs. without cancer (25% v. 14%, respectively). Absence of ASCVD and a more favorable CRF profile were associated with significantly lower expenditures across the spectrum of cancer diagnosis. Among cancer patients, the adjusted mean annual cost for those with and without ASCVD were $11,139 (95% CI [8870, 13408]) and $6,436 (95% CI [5531, 7342]). Among cancer patients without ASCVD, adjusted annual healthcare expenditures among those with optimal versus poor CRF profile were $5,154 (95% CI [4100, 6208]) and $9.058 (95% CI [5562, 12553]).
Conclusion: In a nationally representative US adult population, absence of ASCVD & a favorable CRF profile is associated with significantly lower medical expenditure among cancer patients. Our project provides estimates to continue better CV management and prevention practices, while contextualizing the burden of cancer.
Author Disclosures: J. Singh: None. J. Valero-Elizondo: None. J.A. Salami: None. H. Warraich: None. O. Ogunmoroti: None. E.S. Spatz: None. N. Desai: None. J.S. Rana: None. S.S. Virani: None. R. Blankstein: None. M.J. Blaha: None. K. Nasir: Consultant/Advisory Board; Modest; Quest Diagnostic, Regeneron.
- © 2016 by American Heart Association, Inc.